Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
  • A61K31/404—Indoles, e.g. pindolol
  • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1605—Excipients; Inactive ingredients
  • A61K9/1629—Organic macromolecular compounds
  • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
  • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
  • A61K9/2806—Coating materials
  • A61K9/2833—Organic macromolecular compounds
  • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
  • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

• the present invention relates to a controlled release color stable pharmaceutical dosage forms comprising the active ingredient and other excipients, free of alkalizing or buffering agents.
• the present invention relates to controlled release color stable pharmaceutical dosage wherein the active substance is selected from the group of HMG-CoA reductase inhibitors like statins, most preferably the statin is Fluvastatin and its salts.
• the present invention also relates to the methods for the preparation of controlled release color stable pharmaceutical dosage forms comprising HMG-Co A reductase inhibitor free of alkalizing or buffering agents wherein the granules are independent of particle size.
• US 5,356,896 disclose pharmaceutical composition containing fluvastatin and alkalizing substance capable of imparting a PH of at least 8 to the formulation.
• US 6,558,659 discloses stable pharmaceutical dosage forms containing a ring-opened 7-substituted-3, 5-dihydroxyheptanoic or a ring-opened 7-substituted-3, 5- dihydroxyheptenoic acid, or a pharmaceutically acceptable salt thereof, as an active component and a stabilizing effective amount of at least one amido-group containing polymeric compound or at least one amino-group containing polymeric compound, or combination thereof; wherein the stabilized pharmaceutical composition does not contain a stabilizing effective amount of another stabilizer or a combination of other stabilizers.
• WO 02/076376 discloses stabilization of pravastatin with carriers, which comprise at least one diluent and at least one lubricant.
• EP 336298 US 5,030,447 and US 5,180,589 , respectively, disclose stabilization of pravastatin with basifying substances, selected from, strong bases such as hydroxides of alkali metals and alkaline earth metals, and ammonium hydroxide, preferably specifying the substances such as magnesium oxide, magnesium hydroxide, calcium hydroxide sodium hydroxide, potassium hydroxide and lithium hydroxide, and ammonium hydroxide and magaldrate.
• strong bases such as hydroxides of alkali metals and alkaline earth metals
• ammonium hydroxide preferably specifying the substances such as magnesium oxide, magnesium hydroxide, calcium hydroxide sodium hydroxide, potassium hydroxide and lithium hydroxide, and ammonium hydroxide and magaldrate.
• WO 2000/35425 discloses stabilization of the statins with buffers, among which are listed, for example sodium and potassium citrate, sodium phosphate, disodium phosphate, calcium carbonate, calcium hydrogen phosphate, calcium phosphate, calcium sulfate, sodium or magnesium carbonate, sodium ascorbinate, benzoate, sodium or potassium hydrogen carbonate, sodium or potassium lauryl sulfate and mixtures thereof.
• buffers for example sodium and potassium citrate, sodium phosphate, disodium phosphate, calcium carbonate, calcium hydrogen phosphate, calcium phosphate, calcium sulfate, sodium or magnesium carbonate, sodium ascorbinate, benzoate, sodium or potassium hydrogen carbonate, sodium or potassium lauryl sulfate and mixtures thereof.
• WO 2001/93860 discloses stabilization of statins with co-crystallization and/or co- precipitation of a statin and a buffering or basifying substance in a homogeneous mixture of statins and said buffering or basifying substance.
• the following buffering substances are described, for example sodium and potassium citrate, sodium and potassium phosphate or hydrogen phosphate, dibasic sodium phosphate, sodium, potassium, magnesium or calcium carbonate or hydrogen carbonate, sulfates, aminoguanidine carbonate or hydrogen carbonate, guanidine carbonate or hydrogen carbonate, succinimide carbonate or hydrogen carbonate, 1-adamantil amine carbonate or hydrogen carbonate etc.
• basifying substances for example metallic oxides such as magnesium oxide, aluminium oxide, hydroxides of alkaline and alkaline earth metals and organic bases such as succinimide, 1-adamantil amine, N, N'-bis (2hydroxyethyl) ethylenediamine, tris (hydroxymethyl) aminomethane, D (-)-N-methylglucamine and organic acids with alkaline character such as 3- (N-morpholino) propanesulfonic acid, 4-(cyclohexyl amino)-1-butanesulfonic acid, 4-(cyclohexyl amino)-1-ethansulfonic acid and salts of alkali and alkaline earth metals with said acids or with arginine, ornithine, lysine, etc.
• metallic oxides such as magnesium oxide, aluminium oxide, hydroxides of alkaline and alkaline earth metals and organic bases
• organic bases such as succinimide, 1-adamantil amine, N, N'-bis (2hydroxyethyl)
• EP 547000 and US 5,356,896 discloses stabilization of fluvastatin with an alkaline medium which is either an alkali or a buffer and specifies water-soluble alkaline substances from the group consisting of inorganic carbonate salts such as sodium or potassium carbonate, sodium bicarbonate, potassium hydrogen carbonate, phosphate salts such as anhydrous sodium, potassium or calcium dibasic phosphate, trisodium phosphate and hydroxides of alkaline metals such as sodium, potassium or lithium hydroxide and mixtures thereof.
• inorganic carbonate salts such as sodium or potassium carbonate, sodium bicarbonate, potassium hydrogen carbonate
• phosphate salts such as anhydrous sodium, potassium or calcium dibasic phosphate
• trisodium phosphate such as sodium, potassium or lithium hydroxide and mixtures thereof.
• water insoluble or low soluble alkaline substances such as magnesium oxide, hydroxide or carbonate, magnesium hydrogen carbonate, aluminium or calcium hydroxide and carbonate, combined compounds of aluminum and magnesium such as magnesium aluminium hydroxide, and the phosphoric acid salts such as tribasic calcium phosphate and mixtures thereof.
• WO 03/000239 describes stabilization of pravastatin with buffers such as, e.g. TRIS trometamine and disodium hydrogen phosphate.
• US 6,242,003 describes a color stable sustained release tablet comprising granules comprising fluvastatin and a hydroxypropyl methyl cellulose polymer; wherein the granules have a mean particle size of less than 200 micron. Additionally it also contains hydrophilic polymers like hydroxy propyl cellulose.
• dosage forms comprising HPMC polymers formed gel-like domains upon storage, these domains, still more surprisingly were highly coloured. Whereas this discolouration left the dosage forms with an unsightly, uneven mottled appearance. It was believed that the increased colour stability observed as the mean particle size is decreased may be due to the ability of the finer granules to form a tighter compact when compressed, thereby reducing the incidence and size of any voids in the compacted mass. As the HPMC gels are thought to form in these voids, the smaller their number and/or size, the less tendency there is for gels to form.
• US 2003/0171419 discloses composition comprising fluvastatin and HPMC, which is colour-stable upon prolonged periods of storage. Also it describes granules comprising fluvastatin and HPMC wherein the granules have a mean particle size of less than 200 microns. Further it describes a method of preventing or substantially reducing the formation of gels of hydrated HPMC in a pharmaceutical composition or in granules comprising a fluvastatin and HPMC comprising the step of storing the pharmaceutical composition or granules at a relative humidity not exceeding 75% and at a temperature of between 25°C and 40°C.
• one object of the present invention is to provide a color stable controlled release pharmaceutical dosage form comprising HMG CoA reductase inhibitor, hydroxypropyl methyl cellulose, hydroxypropyl cellulose free of alkalizing, buffering agents and wherein the granules are independent of particle size.
• a color stable controlled release pharmaceutical dosage form comprising granules comprising fluvastatin sodium and a hydroxypropyl cellulose polymer, free of alkalizing, buffering agents, wherein the granules are independent of particle size.
• Another object of the present invention is to provide a process for the preparation of controlled release formulation of Fluvastatin sodium.
• color stable controlled release pharmaceutical dosage comprising of a drug like HMG-Co A reductase inhibitor, hydroxypropyl cellulose, rate controlling polymers and one or more pharmaceutical excipients and free of alkalizing or buffering agents or combinations thereof, wherein the granules are independent of particle size.
• the invention provides A process of making a color stable controlled release dosage form comprising fluvastatin sodium and hydroxypropyl cellulose wherein the drug and excipients granulation is carried out under dry conditions and is capable of being stored at normal atmospheric conditions.
• the present invention is concerned with formulations for controlled release of fluvastatin, free of alkalizing or buffering agents that are independent of particle size of granules.
• the present invention relates to a color stable controlled release pharmaceutical dosages form comprising Fluvastatin, and one or more pharmaceutical excipients, free of alkalizing or buffering agents and which is independent of particle size of granules.
• HPC Hydropropyl cellulose
• compositions comprising, Fluvastatin and hydroxypropyl cellulose of various viscosity grades, provides a stable controlled release formulation, which unlike the prior art is independent of particle size of the granules used. Also these dosage forms do not exhibit the mottled appearance as seen with the prior art dosage form upon prolonged storage at normal atmospheric condition.
• hydrophilic polymers such as hydroxy propyl cellulose result in stable dosage forms, which do not depend upon the particle size of the granules
• Rate controlling polymer according to present invention includes agents, which controls the release of drug from the formulation.
• the agents comprise of hydroxy propyl methylcellulose in the range of less than about 15%, and other hydrophilic polymer as described herein.
• Hydrophilic polymers that may be used in the composition are selected from the group comprising of hydroxyethyl cellulose having a number average molecular weight ranging from 90,000 to 1,300,000, hydroxypropylcellulose having a number average molecular weight of 80,000 to 1,150,000 in the range of less than about 50 % preferably about 15% to about 50% and poly (ethylene oxide) having a number average molecular weight ranging from 100,000 to 500,000, preferably 150,000 to 300,000, more preferably 200,000.
• the scope of the present invention is not limited to the molecular weights of the rate controlling hydrophilic polymers.
• the stable controlled release pharmaceutical dosage form wherein the ratio of the rate controlling polymer hydroxypropyl methylcellulose to hydroxy propylcellulose is from about 1:3.5 to about 1:10.
• HGM-CoA reductase inhibitors e.g. Fluvastatin, pravastatin and atorvastatin are also sensitive to humidity.
• amorphous active pharmaceutical ingredient preferably fluvastatin sodium with a moisture content in the range of about 4% to about 6%, preferably about 5% there is no conversion of amorphous form to crystalline form.
• Test formulation having a LOD content in a range of 5.46 -5.51 is stable and there is no conversion of amorphous form to crystalline form.
• Table 1 Loss on Drying (LOD) Data Batch Details LOD at 105°, under vacuum at 105°C for 3 Hrs. (%w/w) Innovator: Lescol XL 9.28 Test formulation 5.49 Test formulation 5.46 Test formulation 5.51 Loss of drying (LOD) test is carried out in dry air oven under vacuum at 105° till constant weight.
• LOD Loss on Drying
• the pharmaceutical excipients of the color stable controlled release pharmaceutical dosage forms of the present invention are selected from the group comprise of different types of cellulose like hydroxypropyl cellulose.
• Controlled release formulation describes a formulation that does not release active drug substance immediately after oral dosing and that allows a reduction in dosage frequency.
• a controlled release formulation includes but is not limited to extended release, delayed release, sustained release formulations.
• a controlled release formulation may be administered once a day.
• Rate controlling polymer according to present invention includes agents, which controls the release of drug from the formulation.
• controlled release formulations of the present invention are manufactured under normal atmospheric conditions.
• the normal atmospheric conditions under which the tablets are generally manufactured are at a temperature not more than about 25°C and relative humidity of about 40%.
• controlled release formulation is matrix formulation (erodable and non-erodable), diffusion controlled membrane coated or osmotic pumps.
• the color stable controlled release pharmaceutical dosage form comprises of HMG CoA reductase inhibitors like the statins, for example, the following are known: pravastatin, atorvastatin, simvastatin, lovastatin, mevastatin or compactin, fluvastatin, cerivastatin or rivastatin, rosuvastatin or visastatin, and itavastatin or pitavastatin, or nisvastatin and its pharmaceutically acceptable salts.
• statins for example, the following are known: pravastatin, atorvastatin, simvastatin, lovastatin, mevastatin or compactin, fluvastatin, cerivastatin or rivastatin, rosuvastatin or visastatin, and itavastatin or pitavastatin, or nisvastatin and its pharmaceutically acceptable salts.
• US 5356896 discloses a color stable composition comprising a drug and other pharmaceutically acceptable excipients imparting a pH of atleast 8.
• the present scope of the invention comprises of a drug, and one or more pharmaceutical excipients and does not contain alkalizing or buffering substances or combinations thereof, imparting a pH of less than 10.
• Preferred pharmaceutical compositions are tablets, which are formed of granules having a mean granule particle size of less than about 600 micron.
• the particle size analysis for the present invention is carried out using Malvern Method. However, with no more than routine experimentation, the skilled person will be able to determine a suitable granulate size for a given excipients mixture.
• Granules described as herein above comprise of Fluvastatin sodium, rate controlling polymer and one or more pharmaceutical excipients.
• the formulation will, in general comprise of one or more excipients.
• excipients include, but are not limited to, diluents, disintegrants, lubricant, glident, binders, fillers, surfactant, solubilizers, and wetting agents.
• a combination of excipients may also be used.
• excipients include diluents such as mannitol, dextrose, xylitol, sorbitol, gelatin, acacia, sucrose, microcrystalline cellulose, calcium carbonate, calcium phosphate dibasic, calcium phosphate tribasic, calcium sulfate, lactose, starches, vinyl polymers and the likes
• disintegrants referred to in the present invention include one or more of microcrystalline cellulose, croscarmellose sodium, crospovidone, carboxymethyl starch sodium, sodium starch glycolate and the likes
• binders referred to in the present invention include one or more celluloses such as hydroxypropyl cellulose, hydroxy ethyl cellulose, ethyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose or mixtures thereof, acrylates, methacrylates, povidone, sucrose, corn or maize starch, pregelatinized starch and the like, coloring agents such as ferric oxide,
• excipients may optionally contain alkalizing or buffering agents and or antioxidants known to a person skilled in the art.
• the formulation of the present invention may be prepared by conventional techniques well known to those skilled in the art such as wet granulation, Non- aqueous granulation, melt granulation, direct compression or dry compaction (slugging) and the like. Most preferably the formulation of the present invention is prepared by dry compaction and or slugging.
• a process of making a color stable controlled release dosage form comprising fluvastatin and hydroxypropyl cellulose wherein the drug and excipients granulation is carried out under dry conditions, wherein the dry condition is direct compaction or dry compaction (slugging) carried under atmospheric condition.
• the above mentioned stable controlled release pharmaceutical dosage form is capable of being stored at normal atmospheric conditions.
• formulation and/ or dosage form of the present invention may be a tablet or granules filled in capsule or pellet.
• Said dosage form may be uncoated or coated.
• the active substance when required can be coated with film coating which of said invention and provides protection of the active substance from the environmental factors, or coated with any other in the prior art known film coating.
• the dosage forms may be coated with one or more coatings, enteric or film coating as is well known in the art such as shellac, zein, hydroxypropylmethylcellulose, ethyl cellulose, hydroxy propyl cellulose, polymethacrylates, polyvinyl acetate pthalate, cellulose acetate pthalate, triacetin, dibulty sebecate, a mixture of polyethylene glycol, titanium dioxide and the like.
• coatings enteric or film coating as is well known in the art such as shellac, zein, hydroxypropylmethylcellulose, ethyl cellulose, hydroxy propyl cellulose, polymethacrylates, polyvinyl acetate pthalate, cellulose acetate pthalate, triacetin, dibulty sebecate, a mixture of polyethylene glycol, titanium dioxide and the like.
• the coating may be performed by conventional means using commercially available, ready-to-coat preparations, sold under various brand names such as various grades of Opadry®, Dispersions or mixtures thereof and the like.
• Preferably hydroxy propyl cellulose used in the coating solution is in the range of about 30% to about 40%, Talc in the range of about 12% to about 25%, PEG 6000 in the range of about 10% to about 20% and Titanium dioxide in the range of about 14% to about 33%.
• the dissolution of the present invention was carried out in type 1 dissolution apparatus, basket, at 50rpm, at a temperature of 37 ⁇ 0.5°C, in 1000ml of water and may release not more than about 50% of Fluvastatin is released after 2 hours of measurement in said apparatus, from about 50% to about 80% of Fluvastatin is released after 4 hours of measurement in said apparatus, not less than about 80 % of Fluvastatin is released after 8 hours of measurement in said apparatus.
• Table 3 provides the comparative dissolution profile of stable controlled release compositions of Fluvastatin sodium of the present invention and marketed Lescol XL. Time in Hr. AVg. % Cum. Release Lescol XL Test Sample 0.5 6.0 6.0 1 12 12 2 24 28 4 56 59 6 85 85 8 102 100
• the formulation of the present invention may release not more than about 50% of Fluvastatin is released after 2 hours of measurement in said apparatus, from about 50% to about 80% of Fluvastatin is released after 4 hours of measurement in said apparatus, not less than about 80 % of Fluvastatin is released after 8 hours.
• Table 4 provides Stability data of controlled release compositions of Fluvastatin sodium of the present invention when stored at a storage condition of 40°C and 75% RH.
• Formulation Details Test Sample (Limits as per USP 29) %Impurities Initial 3Mnths 40°C/75% RH Fluvastatin N-ethyl Analog ... ... Anti isomer 0.074 0.122 3-keto 5 Hydroxy ... 0.09 Impurity A (Hydroxy diene) 0.097 0.222 Fluvastatin short chain aldehyde ... ... Fluvastatin t-butyl ester ... ... 5 Keto 3 hydroxy ... 0.148 Total Impurities 0.227 0.745 Any other unknown Impurity ... ... Total Unknown Impurities ... ... Highest Unknown Impurity 0.042 0.132

Landscapes

• Health & Medical Sciences (AREA)
• Epidemiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Engineering & Computer Science (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)

Applications Claiming Priority (1)

Publications (2)

Family

ID=39031083

Family Applications (1)

Country Status (2)

Families Citing this family (1)

Citations (5)

Family Cites Families (5)

• 2007
  • 2007-10-04 EP EP07019437A patent/EP1911441A3/fr not_active Withdrawn
  • 2007-10-11 US US11/870,744 patent/US20080102134A1/en not_active Abandoned

Patent Citations (5)

Also Published As

Similar Documents

Legal Events